Scholarlink

<p>Tick-borne encephalitis virus (TBEV) is a neurotropic flavivirus causing severe meningitis, encephalitis, or meningoencephalitis. The blood-brain barrier (BBB) prevents therapeutic agents from reaching the brain; therefore, specific antiviral therapy that can cross the BBB and treat TBEV-induced infection is urgently needed. In this study, nanobodies (NBs) targeting domain III (DIII) of the envelope (E) glycoprotein of TBEV were developed and conjugated to drug delivery nanosystems based on self-assembling dendrimer nanomicelles (DNs) and gold nanoparticles (AuNs) to facilitate BBB passage and viral neutralization. NBs were derived from the variable region of heavy chain-only llama antibodies and panned against DIII using phage display. The most active NBs were conjugated with DNs and AuNs. Remarkably, the dendrimer nanosystem decorated with the nanobody clone TA3 (TA3-DNs) and the peptide Angiopep-2 effectively crossed the BBB model and neutralized TBEV. Therefore, TA3-DNs constitute a promising candidate for treating TBEV, and merit further validation in animal models for future translational studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nanobody conjugated with dendrimer nanoparticles effectively neutralizes tick-borne encephalitis virus

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月10日

查看全文
  • Jana Jozefiaková,
  • Amod Kulkarni,
  • Dinesh Dhumal,
  • Ádám Kevély,
  • Eva Nováková,
  • Kamila Koči,
  • Ling Peng,
  • Juraj Koči,
  • Mangesh Bhide

摘要

Tick-borne encephalitis virus (TBEV) is a neurotropic flavivirus causing severe meningitis, encephalitis, or meningoencephalitis. The blood-brain barrier (BBB) prevents therapeutic agents from reaching the brain; therefore, specific antiviral therapy that can cross the BBB and treat TBEV-induced infection is urgently needed. In this study, nanobodies (NBs) targeting domain III (DIII) of the envelope (E) glycoprotein of TBEV were developed and conjugated to drug delivery nanosystems based on self-assembling dendrimer nanomicelles (DNs) and gold nanoparticles (AuNs) to facilitate BBB passage and viral neutralization. NBs were derived from the variable region of heavy chain-only llama antibodies and panned against DIII using phage display. The most active NBs were conjugated with DNs and AuNs. Remarkably, the dendrimer nanosystem decorated with the nanobody clone TA3 (TA3-DNs) and the peptide Angiopep-2 effectively crossed the BBB model and neutralized TBEV. Therefore, TA3-DNs constitute a promising candidate for treating TBEV, and merit further validation in animal models for future translational studies.